Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hyoscyamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 known ✓ | P11229 | 5/20 | 0.91 |
| ▸ | CHRM2 known ✓ | P08172 | 5/20 | 0.91 |
| ▸ | CHRM3 known ✓ | P20309 | 4/20 | 0.91 |
| ▸ | MAPT | P10636 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.91 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.91 |
| ▸ | LMNA | P02545 | 3/20 | 0.91 |
| ▸ | HTR2C | P28335 | 2/20 | 0.91 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.91 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.91 |
| ▸ | MEN1 | O00255 | 1/20 | 0.91 |
| ▸ | POLB | P06746 | 1/20 | 0.91 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.91 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.91 |
| ▸ | HRH1 | P35367 | 1/20 | 0.91 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.91 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.91 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Atropine SCHEMBL27510472 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL3050622 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL28275981 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Endo-Atropine SCHEMBL29555014 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL1411666 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31133 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL2406485 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL31132 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34274 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 | |
| Atropine SCHEMBL34275 | 1.00 | MAPT (1.00) | MAPTALDH1A1CHRM1CHRM2CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2808 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250213727-A1 | DOMINANT-NEGATIVE TUMOR NECROSIS FACTOR ALPHA ADENO-ASSOCIATED VIRUS GENE THERAPY | REGENXBIO INC. | 2025-07-03 | — | — | US | claimed |
| EP-4499154-A1 | DOMINANT-NEGATIVE TUMOR NECROSIS FACTOR ALPHA ADENO-ASSOCIATED VIRUS GENE THERAPY | REGENXBIO Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| CN-117797215-A | Extraction, separation and purification, detection method and application of radix seu herba Tetrastigmatis Hypoglauci total alkaloids | 安康市食品药品检验检测中心(药械不良反应监测中心) | 2024-04-02 | — | — | CN | claimed |
| CN-117741010-A | Method for simultaneously detecting hyoscyamine sulfate and scopoletin in belladonna extract or product containing belladonna extract | 辽宁省检验检测认证中心 | 2024-03-22 | — | — | CN | claimed |
| CN-117030908-A | Method for rapidly determining belladonna content | 石药集团江西金芙蓉药业股份有限公司 | 2023-11-10 | — | — | CN | claimed |
| WO-2023183623-A1 | DOMINANT-NEGATIVE TUMOR NECROSIS FACTOR ALPHA ADENO-ASSOCIATED VIRUS GENE THERAPY | REGENXBIO INC. (US) | 2023-09-28 | — | — | WO | claimed |
| US-20230082167-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC (US) | 2023-03-16 | — | — | US | claimed |
| EP-3950692-A1 | NOVEL TRICYCLIC COMPOUNDS | AbbVie Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| CN-113786437-A | Belladonna liquid extract production process | 安徽恒达药业有限公司 | 2021-12-14 | — | — | CN | claimed |
| US-20210361827-A1 | ELASTIC BIORESORBABLE ENCASEMENT FOR IMPLANTS | FOUNDRY THERAPEUTICS, INC. | 2021-11-25 | — | — | US | claimed |
| EP-1119345-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2001-08-01 | — | — | EP | claimed |
| EP-0572932-B1 | Method and implant device for long term delivery of drugs | BARD INC C R (US) | 2000-09-13 | — | — | EP | claimed |
| WO-2000021504-A1 | ENCAPSULATION OF SENSITIVE LIQUID COMPONENTS INTO A MATRIX TO OBTAIN DISCRETE SHELF-STABLE PARTICLES | GENERAL MILLS, INC. (US) | 2000-04-20 | — | — | WO | claimed |
| EP-0935523-A4 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GEN MILLS INC (US) | 1999-12-29 | — | — | EP | claimed |
| EP-0935523-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | GENERAL MILLS, INC. (US) | 1999-08-18 | — | — | EP | claimed |
| WO-1999030690-A1 | ORAL DELIVERY FORMULATION | AXIA THERAPEUTICS, INC. (US) | 1999-06-24 | — | — | WO | claimed |
| WO-1998018610-A1 | EMBEDDING AND ENCAPSULATION OF CONTROLLED RELEASE PARTICLES | LENGERICH BERNHARD H VAN (US) | 1998-05-07 | — | — | WO | claimed |
| US-5629008-A | Method and device for long-term delivery of drugs | C.R. BARD, INC. (US) | 1997-05-13 | — | — | US | claimed |
| WO-1995033511-A1 | METHOD AND DEVICE FOR LONG-TERM DELIVERY OF DRUGS | C.R. BARD, INC. (US) | 1995-12-14 | — | — | WO | claimed |
| EP-0572932-A2 | Method and implant device for long term delivery of drugs | C.R. BARD, INC. (US) | 1993-12-08 | — | — | EP | claimed |